US Patent Issued to The Texas A&M University System on Sept. 2 for "Method of depleting target antigen-specific antibody from a patient by administering a fusion protein (Seldeg) for selectively depleting antigen-specific antibodies" (British, American Inventors)

ALEXANDRIA, Va., Sept. 3 -- United States Patent no. 12,404,339, issued on Sept. 2, was assigned to The Texas A&M University System (College Station, Texas).

"Method of depleting target antigen-specific antibody from a patient by administering a fusion protein (Seldeg) for selectively depleting antigen-specific antibodies" was invented by Elizabeth Sally Ward Ober (Southampton, Great Britain), Venkata Siva Charan Devanaboyina (College Station, Texas) and Raimund Johannes Ober (Southampton, Great Britain).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure includes a fusion protein, called a "Seldeg", including a targeting component that specifically binds to a cell surface receptor or other ...